Table 1 Clinical and biochemical characteristics of study patients.

From: Effect of Treatment on Body Fluid in Patients with Unilateral Aldosterone Producing Adenoma: Adrenalectomy versus Spironolactone

 

Adrenalectomy

Spironolactone

p

Patients(n)

21

20

 

Demography

 Male (%)

12(57.1%)

11(55.0%)

0.766

 Age (y/o)

58.25 ± 21.92

57.25 ± 4.95

0.754

 BMI(kg/m2)

24.9 ± 4.1

24.5 ± 3.1

0.897

 MAP(mmHg)

107.7 ± 14.2

103.9 ± 14.2

0.421

 DM, n (%)

2 (9.5%)

3 (15%)

0.643

Aldosteronism profile

 Sodium (mmol/L)

139.1 ± 1.9

140.8 ± 3.5

0.157

 Potassium (mmol/L)

3.62 ± 0.52

4.34 ± 0.88

0.004

 PAC (ng/dL) *

38.1(33.3–54.7)

53.3(36.5–80.7)

0.149

 Log ARR

2.42 ± 0.68

1.92 ± 0.86

0.082

 UNa (mmol/L)

59.3 ± 34.8

73.1 ± 44.5

0.347

 UK (mmol/L)

31.6 ± 20.8

33.1 ± 13.6

0.443

Body composition

 Relative OH (%)

2.51 ± 5.45

5.12 ± 4.63

0.176

 Relative fat (%)

28.8 ± 8.5

28.9 ± 6.9

0.897

 Relative LTM (%)

59.7 ± 11.2

59.0 ± 8.8

0.988

Other variables

 HOMA-IR (mU/L·mmol/L)

39.4 ± 40.0

45.8 ± 62.7

0.664

 C-reactive protein (mg/L)

1.52 ± 2.13

1.93 ± 2.16

0.433

 TNF-α (pg/ml)

8.47 ± 4.23

5.18 ± 1.56

0.009

 NT-proBNP (pg/ml)

2.83 ± 2.82

6.07 ± 9.78

0.165

 ACR (mg/mg)

0.47 ± 0.12

0.81 ± 0.21

0.393

 Creatinine (mg/dl)

1.09 ± 0.59

0.93 ± 0.26

0.574

 Cystatin C (mg/dl)

0.78 ± 0.14

0.82 ± 0.22

0.779

Categories of hypertensive drugs before recruitment

 β- blockers (%)

7 (33.3)

5 (25)

0.789

 ACEI/ ARB (%)

6 (28.6)

7 (35)

0.542

  1. Abbreviations: ACEI, angiotensin-converting enzyme inhibitors; ACR, Urine albumin-to-creatinine ratio ; APA, aldosterone producing adenoma; ARB, angiotensin II receptor blockers; ARR, aldosterone-renin ratio (ng/dL per ng/mL/h); BMI, body mass index; DM, Diabetes mellitus; HOMA-IR, homeostasis model assessment for insulin resistance; MAP, mean arterial blood pressure; NT-proBNP, N-terminal pro-brain natriuretic peptide; LTM, lean total mass; OH, overhydration; PAC, plasma aldosterone concentration ; TNF-α, Tumor necrosis factor-alpha; UK, urine potassium; UNa, urine sodium.
  2. Data were provided as the mean values ± standard deviation, Significance was determined by Wilcoxon signed rank test in nonparametric distribution.
  3. *Median (interquartile range).
  4. Note: To convert potassium in mmol/L to mEq/L, multiple by 1; PAC in ng/dL to nmol/L, multiple by 0.02774; PRA in ng/mL/hr to ng/(Lxs), multiple by 0.2778.
Back to article page